See What HealthDay Can Do For You
Contact Us

Pramlintide Effective Adjunctive Therapy for Diabetes

Modest improvements seen in HbA1c and weight in some with types 1 and 2 diabetes

THURSDAY, Nov. 11 (HealthDay News) -- The synthetic amylin analogue pramlintide appears to be somewhat more effective than placebo as adjunctive treatment for diabetes in several clinical scenarios, according to research published in the November/December issue of the Annals of Family Medicine.

Nancy J. Lee, of the Oregon Health & Science University in Portland, and colleagues conducted a systematic review of randomized controlled trials studying the efficacy, effectiveness, and harms of pramlintide as adjunct therapy in adults and children with type 1 or type 2 diabetes. Seven trials met the inclusion criteria. Due to heterogeneity of data, a meta-analysis could not be performed and only qualitative data were synthesized.

The researchers found that pramlintide was more effective than placebo for type 1 diabetes in patients using conventional (but not intensive) insulin therapy, with a difference in HbA1c levels of 0.2 to 0.3 percent in two studies. In patients with type 2 diabetes on flexibly-dosed glargine (without prandial insulin) or fixed-dose insulin therapies, with or without oral hypoglycemic agents, pramlintide was also more effective than placebo at reducing HbA1c, with a difference of approximately 0.4 percent. Patients with type 1 and type 2 diabetes lost weight on pramlintide, while those on placebo showed a tendency toward weight gain, but patients on pramlintide also had more frequent nausea and severe hypoglycemia.

"Pramlintide may have a role in glycemic control in some patients with type 1 or type 2 diabetes. Although improvements in HbA1c levels are small, incremental improvements in HbA1c levels of 0.2 to 0.4 percent from the addition of pramlintide may ultimately contribute to long-term glycemic control and cardiovascular health when combined with other means of improving glycemic control," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.